EAU 2013 - Programme Book - YouMed

Saturday
Saturday, 16 March - EAU Programme
78 Programme Book
Abstract Session
08.30 - 10.00 Prostate cancer screening
Brown Hall 1-2 - Level S2
Poster Session 1
Chairs: J.E. Hugosson, Gothenburg (SE)
M.J. Roobol, Rotterdam (NL)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion.
1 Screening for prostate cancer: Results of the Rotterdam section of the European Randomized study of
Screening for Prostate Cancer (ERSPC)
M.J. Roobol, C.H. Bangma, F.H. Schröder (Rotterdam, The Netherlands)
2 Incidence and mortality of prostate cancer after termination of PSA based screening
A.L.A. Grenabo, E. Holmberg, S. Moss, J. Hugosson (Gothenburg, Sweden; London, United Kingdom)
3 Repeat transrectal prostate biopsies incorporating targeted anterior zone sampling – is template biopsy
really necessary?
A. Pandit, H. Thomas, C. O’Brien, J. Featherstone, N. Fenn, P. Bose (Swansea, United Kingdom)
4 Men with total PSA levels between 1-2.99 ng/mL at initial screening have an elevated risk of future
prostate cancer diagnosis: Results from the Gothenburg randomized screening trial
M. Frånlund, S. Carlsson, H. Lilja, J. Hugosson (Gothenburg, Sweden; New York, United States of America)
5 Disease-specific survival of men with screen-detected prostate cancer: Comparison of first round vs
second round cancers in an European randomized screening trial
X. Zhu, M. Bul, L.P. Bokhorst, C.H. Bangma, F.H. Schröder, M.J. Roobol (Rotterdam, The Netherlands)
6 Serum cholesterol mediates in the mechanism of statins to prevent prostate cancer
C. Konstantinidis Garay, I. Iztueta, F. Agreda, A. Celma, J.M. Bastarós, J. Placer, J. Planas, J. Morote
(Barcelona, Spain)
7 PSA-Isoforms-Velocity. Evaluation of a novel approach in the early diagnosis of prostate cancer. Results
from the Tyrol PSA screening project
I. Heidegger, H. Klocker, V. Skradski, M. Ladurner, E. Steiner, G. Schaefer, W. Horninger, J. Bektic (Innsbruck,
Austria)
8 Cost-benefit analysis in Japanese PSA screening in 5-years aged ranking
K. Okihara, K. Ito, T. Miki, S. Kazuhiro, T. Iinuma (Kyoto, Maebashi, Tokyo, Japan)
9 Performance of inherited genetic markers to predict prostate biopsy outcomes in Chinese men
H.W. Jiang, F. Liu, L. Zhang, H. Zhang, R. Na, X. Lin, Q. Ding, J. Xu (Shanghai, China)
10 Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an
opportunistic screening programme for prostate cancer
J. Rubio Briones, J. Casanova, R. Dumont, A. Fernández-Serra, I. Casanova-Salas, J. Domínguez-Escrig,
M. Ramírez-Backhaus, A. Collado, A. Gómez-Ferrer, I. Iborra, J.V. Ricós, J.L. Monrós, E. Solsona, J.A. López-
Guerrero (Valencia, Spain)
11 One-year results of a multidisciplinary prostate cancer unit: Management changes in comparison with a
monodisciplinary unit
A. Sciarra, V. Gentile, S. Salciccia, A. Gentilucci, S. Cattarino, V. Gentile, V. Panebianco (Rome, Italy)